v3.26.1
Product and Geographic Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Product and Geographic Information Product and Geographic Information
Revenues of the Company’s products were as follows:
Three Months Ended March 31,
20262025
($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Women’s Health
Nexplanon/Implanon NXT$127 $74 $201 $176 $72 $248 
Follistim AQ21 39 61 35 34 69 
NuvaRing
6 18 24 6 16 22 
Ganirelix Acetate Injection
2 24 26 5 23 27 
Marvelon/Mercilon
— 26 26 — 39 39 
Jada5 — 5 15 — 15 
Other Women’s Health (1)
17 30 46 15 27 43 
General Medicines
Biosimilars
Renflexis42 15 57 44 12 57 
Hadlima51 16 67 33 14 47 
Ontruzant4 1 5 4 14 18 
Brenzys— 20 20 — 14 14 
Other Biosimilars (1)
11 13 24 — 5 5 
Established Brands
Cardiovascular
Atozet— 85 85 — 77 77 
Zetia1 86 87 1 84 85 
Cozaar/Hyzaar2 55 57 2 53 55 
Vytorin1 20 21 1 22 23 
Rosuzet— 6 6 — 4 4 
Other Cardiovascular (1)
1 27 28 — 30 30 
Respiratory
Singulair2 38 40 2 72 74 
Nasonex— 65 65 — 71 72 
Dulera23 12 35 34 10 43 
Clarinex1 30 31 — 34 34 
Other Respiratory (1)
11 1 12 10 3 13 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 59 59 — 62 62 
Fosamax— 29 29 1 32 33 
Diprospan— 35 35 — 30 30 
Vtama
23 2 25 20 4 24 
Other Non-Opioid Pain, Bone and Dermatology (1)
3 65 68 4 65 68 
Other
Propecia1 28 30 1 24 26 
Emgality— 54 54 — 32 32 
Proscar— 26 26 — 24 24 
Other (1)
3 85 87 3 76 78 
Other (2)
— 18 18 — 22 22 
Revenues$358 $1,102 $1,460 $412 $1,101 $1,513 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately.
(2) Includes manufacturing sales to third parties.
Revenues by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20262025
Europe and Canada$412 $376 
United States358 412 
Asia Pacific and Japan226 251 
China194 204 
Latin America, Middle East, Russia, and Africa
247 240 
Other (1)
23 30 
Revenues$1,460 $1,513 
(1) Includes manufacturing sales to third parties.